The study is examining how safe and effective a medicine called trimodulin is for adults with a serious type of lung infection called severe community-acquired pneumonia (sCAP). People with sCAP often need help breathing using a machine called invasive mechanical ventilation (IMV). In this study, trimodulin is given alongside normal care and compared to a placebo, which is a substance with no active medicine. The study is double-blind, meaning neither the patients nor the doctors know who gets the trimodulin or placebo. Participants will receive the treatment for 5 days, and the study will follow their progress for up to 90 days.

• Study involves up to 90 days of follow-up.
• Participants must be adults, not pregnant, and not have COVID-19.
• Treatment is given daily for 5 days, with close monitoring afterward.

Before joining, participants must have signs of pneumonia, need IMV, and meet other health criteria. They cannot join if they have certain other illnesses or recent participation in another study. This is important to make sure the study results are accurate and safe for everyone.